Last reviewed · How we verify
Placebo to Tolterodine
Placebo to Tolterodine is a Muscarinic M3 receptor antagonist Small molecule drug developed by Astellas Pharma Inc. It is currently in Phase 3 development for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.
Tolterodine is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms.
Tolterodine is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.
At a glance
| Generic name | Placebo to Tolterodine |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Drug class | Muscarinic M3 receptor antagonist |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Tolterodine selectively blocks M3 muscarinic receptors on the detrusor muscle of the bladder, preventing acetylcholine-induced contractions. This reduces the frequency and urgency of urination and increases bladder capacity. The drug has relative selectivity for bladder M3 receptors over salivary gland M3 receptors, which may reduce certain anticholinergic side effects compared to non-selective agents.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
Common side effects
- Dry mouth
- Headache
- Constipation
- Dizziness
- Blurred vision
- Urinary retention
Key clinical trials
- TReating Incontinence for Underlying Mental and Physical Health (PHASE4)
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (PHASE2)
- A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder (PHASE3)
- Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up. (PHASE1)
- Over Active Bladder Patients Having Sling Surgery (NA)
- An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Tolterodine CI brief — competitive landscape report
- Placebo to Tolterodine updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI
Frequently asked questions about Placebo to Tolterodine
What is Placebo to Tolterodine?
How does Placebo to Tolterodine work?
What is Placebo to Tolterodine used for?
Who makes Placebo to Tolterodine?
What drug class is Placebo to Tolterodine in?
What development phase is Placebo to Tolterodine in?
What are the side effects of Placebo to Tolterodine?
What does Placebo to Tolterodine target?
Related
- Drug class: All Muscarinic M3 receptor antagonist drugs
- Target: All drugs targeting M3 muscarinic acetylcholine receptor
- Manufacturer: Astellas Pharma Inc — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Overactive bladder with symptoms of urge incontinence, urgency, and frequency
- Compare: Placebo to Tolterodine vs similar drugs
- Pricing: Placebo to Tolterodine cost, discount & access